Cytosorbents Corp (CTSO) Given a $12.00 Price Target by HC Wainwright Analysts
Cytosorbents Corp (OTCMKTS:CTSO) has been given a $12.00 price objective by analysts at HC Wainwright in a research note issued on Tuesday. The brokerage currently has a a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 100.00% from the company’s current price.
Several other equities analysts also recently issued reports on CTSO. Maxim Group reissued a “buy” rating on shares of Cytosorbents Corp in a report on Wednesday, June 15th. Brean Capital initiated coverage on shares of Cytosorbents Corp in a report on Tuesday, October 4th. They set a “buy” rating and a $24.00 price target for the company. Finally, B. Riley initiated coverage on shares of Cytosorbents Corp in a report on Thursday, October 6th. They set a “buy” rating and a $11.25 price target for the company. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $13.65.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) traded up 0.84% during midday trading on Tuesday, reaching $6.00. 223,211 shares of the company were exchanged. Cytosorbents Corp has a 52-week low of $3.11 and a 52-week high of $8.10. The firm’s 50 day moving average is $5.74 and its 200-day moving average is $4.81. The company’s market capitalization is $152.62 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/cytosorbents-corp-ctso-given-a-12-00-price-target-by-hc-wainwright-analysts-2.html
Cytosorbents Corp (OTCMKTS:CTSO) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $2.18 million. On average, equities analysts forecast that Cytosorbents Corp will post ($0.39) earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of the company. Advisor Group Inc. acquired a new stake in shares of Cytosorbents Corp during the second quarter valued at approximately $1,372,000. Raymond James & Associates boosted its stake in shares of Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares during the period. Vanguard Group Inc. boosted its stake in shares of Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares during the period. Finally, Douglass Winthrop Advisors LLC acquired a new stake in shares of Cytosorbents Corp during the second quarter valued at approximately $321,000.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.